Sigma Planning Corp Sells 7,192 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sigma Planning Corp trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,213 shares of the biotechnology company's stock after selling 7,192 shares during the quarter. Sigma Planning Corp's holdings in Sarepta Therapeutics were worth $503,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Handelsbanken Fonder AB grew its stake in shares of Sarepta Therapeutics by 5.7% during the fourth quarter. Handelsbanken Fonder AB now owns 16,815 shares of the biotechnology company's stock valued at $1,621,000 after purchasing an additional 900 shares during the last quarter. CWM LLC grew its stake in shares of Sarepta Therapeutics by 178.7% during the fourth quarter. CWM LLC now owns 577 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 370 shares during the last quarter. abrdn plc bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $14,159,000. Vontobel Holding Ltd. grew its stake in shares of Sarepta Therapeutics by 12.8% during the fourth quarter. Vontobel Holding Ltd. now owns 25,278 shares of the biotechnology company's stock valued at $2,438,000 after purchasing an additional 2,863 shares during the last quarter. Finally, WCM Investment Management LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $600,000. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of recent research reports. Citigroup raised their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Needham & Company LLC reduced their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $128.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. UBS Group raised their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a "buy" rating in a research note on Friday, March 1st. Finally, Mizuho raised their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Wednesday, February 14th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $158.38.

Sarepta Therapeutics Stock Up 1.1 %

Shares of NASDAQ:SRPT traded up $1.38 during midday trading on Friday, reaching $128.77. 1,236,000 shares of the company were exchanged, compared to its average volume of 997,301. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The stock has a fifty day simple moving average of $126.22 and a two-hundred day simple moving average of $110.43. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.24) earnings per share. On average, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company's stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company's stock, valued at approximately $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the transaction, the director now directly owns 6,621 shares of the company's stock, valued at approximately $814,118.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. Corporate insiders own 7.40% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.